Login to Your Account

Pharma: Clinic Roundup

Monday, July 8, 2013
The FDA has approved new labeling for Isentress (raltegravir), by Merck & Co. Inc., of Whitehouse Station, N.J. Including 240-week results from the STARTMRK study, a double-blind, Phase III noninferiority trial evaluating an integrase inhibitor for treatment-naive adults patients with HIV-1 infection.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription